What’s Next At Dr Reddy’s: Biologics CDMO, Cell And Gene Therapy Push
Executive Summary
Indian firms are getting their act together in areas like cell and gene therapy, with Dr Reddy’s aiming big and readying a facility alongside an alliance with a Chinese firm for a CAR-T therapy. The company is also doubling down in contract development and manufacturing, with an eye on opportunities in biologics.
You may also be interested in...
Dr Reddy’s Gears For Generic Revlimid Run In US, Quarterly ‘Blips’ Aside
Quarterly ups and down notwithstanding, Dr Reddy’s signals continuing US launch momentum, with its generic Revlimid, for which the Indian firm claims exclusivity for two strengths, set to hit the market next month. “Low competition” assets, especially injectables, also continue to be on the deal-making radar in the US.
Korean Firms Hunt For Overseas Biologics Manufacturers To Support Growth
Korean companies, including large conglomerates and non-biopharmas, are increasingly jumping into biologics manufacturing through cross-border acquisitions following the successes of Samsung and SK.
Industry Flying High With Record-Breaking First Novel Launch Tally in 2021
2021 was another record-breaking year for novel product launches as COVID-19 continued to make an impact, but the industry’s response to the pandemic did not fully account for the acceleration seen in this strict measure of R&D productivity.